{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:55:02Z","timestamp":1781639702983,"version":"3.54.5"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This is the gene therapy trial in patients with Charcot-Marie-Tooth disease type 1A (CMT1A). Intramuscular injections of VM202, a plasmid DNA encoding human hepatocyte growth factor, was investigated for safe and exploratory effective in patients with CMT1A.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study was an open-label single-arm phase 1\/2a trial. Thirteen patients with CMT1A were screened, and 12 consented and enrolled between September 2020 and November 2020. Patients received intramuscular injections of 14\u2009mg of VM202 at baseline, and on days 14, 90, and 104 in both legs. Safety evaluations and clinical assessments using the CMT neuropathy score version 2 (CMTNSv2), CMT examination score (CMTES), Rasch-modified CMTNSv2 (CMTNSv2-R), Rasch-modified CMTES (CMTES-R), functional disability scale (FDS), overall neuropathy limitation score, and 10-meter walk test were performed throughout a 270-day follow-up period. A Wilcoxon signed-rank test was used for statistical comparisons of continuous variables.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The primary objective of this study was to assess the safety and tolerability of intramuscular injections of VM202 in patients with CMT1A. All participants tolerated VM202 well, without any serious adverse events related to the study drug. The secondary objective was to evaluate exploratory efficacy. CMTNSv2, CMTES, CMTNSv2-R, and CMTES-R decreased between baseline and day 270 with mean decreases of 2.17, 2.50, 2.08, and 2.33 points, respectively (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01). Also, FDS decreased with a mean percent decrease of 0.58 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). However, ONLS leg scale and 10-meter walk test were not statistically significant changes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Intramuscular injections of a VM202 appear to be safe and tolerated in CMT1A patients with an exploratory efficacy warrant confirmation in a phase 2b randomized controlled trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration Information<\/jats:title>\n                    <jats:p>\n                      Name of the trial registry (VM202 for CMT1A), Registration number (NCT05361031), URL of the registry (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.clinicaltrials.gov\" ext-link-type=\"uri\">http:\/\/www.clinicaltrials.gov<\/jats:ext-link>\n                      ) and date of registration (2022\u201303-31, retrospectively registered).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-026-04252-2","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T08:06:00Z","timestamp":1772697960000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["An open-label single-arm phase 1\/2a study to evaluate the safety and exploratory efficacy of a VM202 in patients with Charcot-Marie-Tooth disease 1A"],"prefix":"10.1186","volume":"21","author":[{"given":"Hye Mi","family":"Kwon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Su","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Ah","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo Hyun","family":"Nam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Beom","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5459-1772","authenticated-orcid":false,"given":"Byung-Ok","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,5]]},"reference":[{"issue":"7","key":"4252_CR1","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/S1474-4422(09)70110-3","volume":"8","author":"D Pareyson","year":"2009","unstructured":"Pareyson D, Marchesi C. Diagnosis, natural history, and management of Charcot-Marie-Tooth disease. Lancet Neurol. 2009;8(7):654\u201367.","journal-title":"Lancet Neurol"},{"issue":"3","key":"4252_CR2","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1097\/00005072-199603000-00004","volume":"55","author":"C Haney","year":"1996","unstructured":"Haney C, Snipes GJ, Shooter EM, Suter U, Garcia C, Griffin JW, et al. Ultrastructural distribution of PMP22 in Charcot-Marie-Tooth disease type 1A. J Neuropathol Exp Neurol. 1996;55(3):290\u201399.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"11","key":"4252_CR3","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1097\/NEN.0b013e3181598294","volume":"66","author":"H Koike","year":"2007","unstructured":"Koike H, Iijima M, Mori K, Yamamoto M, Hattori N, Katsuno M, et al. Nonmyelinating Schwann cell involvement with well-preserved unmyelinated axons in Charcot-Marie-Tooth disease type 1A. J Neuropathol Exp Neurol. 2007;66(11):1027\u201336.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"Pt 2","key":"4252_CR4","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1093\/brain\/awh693","volume":"129","author":"E Gallardo","year":"2006","unstructured":"Gallardo E, Garcia A, Combarros O, Berciano J. Charcot-Marie-Tooth disease type 1A duplication: spectrum of clinical and magnetic resonance imaging features in leg and foot muscles. Brain. 2006;129(Pt 2):426\u201337.","journal-title":"Brain"},{"issue":"5","key":"4252_CR5","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1212\/01.wnl.0000297553.36441.ce","volume":"70","author":"ME Shy","year":"2008","unstructured":"Shy ME, Chen L, Swan ER, Taube R, Krajewski KM, Herrmann D, et al. Neuropathy progression in Charcot-Marie-Tooth disease type 1A. Neurology. 2008;70(5):378\u201383.","journal-title":"Neurology"},{"issue":"1","key":"4252_CR6","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1186\/s13023-021-02040-8","volume":"16","author":"S Attarian","year":"2021","unstructured":"Attarian S, Young P, Brannagan TH, Adams D, Van Damme P, Thomas FP, et al. A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot-Marie-Tooth type 1A. Orphanet J Rare Dis. 2021;16(1):433.","journal-title":"Orphanet J Rare Dis"},{"issue":"13","key":"4252_CR7","doi-asserted-by":"publisher","first-page":"6755","DOI":"10.3390\/ijms22136755","volume":"22","author":"P Miniou","year":"2021","unstructured":"Miniou P, Fontes M. Therapeutic development in Charcot Marie Tooth type 1 disease. Int J Mol Sci. 2021;22(13):6755.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4252_CR8","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1111\/j.1440-1746.2010.06549.x","volume":"26 Suppl","author":"T Nakamura","year":"2011","unstructured":"Nakamura T, Sakai K, Nakamura T, Matsumoto K. Hepatocyte growth factor twenty years on: much more than a growth factor. J Gastroenterol Hepatol. 2011;26 Suppl(1):188\u2013202.","journal-title":"J Gastroenterol Hepatol"},{"issue":"7","key":"4252_CR9","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1097\/00001756-200105250-00022","volume":"12","author":"N Hashimoto","year":"2001","unstructured":"Hashimoto N, Yamanaka H, Fukuoka T, Dai Y, Obata K, Mashimo T, et al. Expression of HGF and cMet in the peripheral nervous system of adult rats following sciatic nerve injury. Neuroreport. 2001;12(7):1403\u201307.","journal-title":"Neuroreport"},{"issue":"1","key":"4252_CR10","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S0169-328X(01)00284-4","volume":"97","author":"N Hashimoto","year":"2001","unstructured":"Hashimoto N, Yamanaka H, Fukuoka T, Obata K, Mashimo T, Noguchi K. Expression of hepatocyte growth factor in primary sensory neurons of adult rats. Brain Res Mol Brain Res. 2001;97(1):83\u201388.","journal-title":"Brain Res Mol Brain Res"},{"issue":"3","key":"4252_CR11","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1111\/cts.12977","volume":"14","author":"JA Kessler","year":"2021","unstructured":"Kessler JA, Shaibani A, Sang CN, Christiansen M, Kudrow D, Vinik A, et al. Gene therapy for diabetic peripheral neuropathy: a randomized, placebo-controlled phase III study of VM202, a plasmid DNA encoding human hepatocyte growth factor. Clin Transl Sci. 2021;14(3):1176\u201384.","journal-title":"Clin Transl Sci"},{"issue":"24","key":"4252_CR12","doi-asserted-by":"publisher","first-page":"3341","DOI":"10.1101\/gad.11.24.3341","volume":"11","author":"F Maina","year":"1997","unstructured":"Maina F, Hilton MC, Ponzetto C, Davies AM, Klein R. Met receptor signaling is required for sensory nerve development and HGF promotes axonal growth and survival of sensory neurons. Genes Dev. 1997;11(24):3341\u201350.","journal-title":"Genes Dev"},{"issue":"8","key":"4252_CR13","doi-asserted-by":"publisher","first-page":"5187","DOI":"10.1074\/jbc.272.8.5187","volume":"272","author":"V Wong","year":"1997","unstructured":"Wong V, Glass DJ, Arriaga R, Yancopoulos GD, Lindsay RM, Conn G. Hepatocyte growth factor promotes motor neuron survival and synergizes with ciliary neurotrophic factor. J Biol Chem. 1997;272(8):5187\u201391.","journal-title":"J Biol Chem"},{"issue":"5","key":"4252_CR14","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1111\/j.1471-4159.2005.03446.x","volume":"95","author":"N Ishihara","year":"2005","unstructured":"Ishihara N, Takagi N, Niimura M, Takagi K, Nakano M, Tanonaka K, et al. Inhibition of apoptosis-inducing factor translocation is involved in protective effects of hepatocyte growth factor against excitotoxic cell death in cultured hippocampal neurons. J Neurochem. 2005;95(5):1277\u201386.","journal-title":"J Neurochem"},{"issue":"25","key":"4252_CR15","doi-asserted-by":"publisher","first-page":"13901","DOI":"10.1073\/pnas.240305897","volume":"97","author":"P Pasinelli","year":"2000","unstructured":"Pasinelli P, Houseweart MK, Brown RH Jr, Cleveland DW. Caspase-1 and -3 are sequentially activated in motor neuron death in Cu, Zn superoxide dismutase-mediated familial amyotrophic lateral sclerosis. Proc Natl Acad Sci USA. 2000;97(25):13901\u201306.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6805","key":"4252_CR16","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/35037739","volume":"407","author":"J Yuan","year":"2000","unstructured":"Yuan J, Yankner BA. Apoptosis in the nervous system. Nature. 2000;407(6805):802\u201309.","journal-title":"Nature"},{"key":"4252_CR17","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.omtn.2018.06.013","volume":"12","author":"W Choi","year":"2018","unstructured":"Choi W, Lee J, Lee J, Ko KR, Kim S. Hepatocyte growth factor regulates the miR-206-HDAC4 cascade to control neurogenic muscle atrophy following surgical denervation in mice. Mol Ther Nucleic Acids. 2018;12:568\u201377.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"12","key":"4252_CR18","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1038\/gt.2010.101","volume":"17","author":"WB Pyun","year":"2010","unstructured":"Pyun WB, Hahn W, Kim DS, Yoo WS, Lee SD, Won JH, et al. Naked DNA expressing two isoforms of hepatocyte growth factor induces collateral artery augmentation in a rabbit model of limb ischemia. Gene Ther. 2010;17(12):1442\u201352.","journal-title":"Gene Ther"},{"issue":"3\u20134","key":"4252_CR19","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1080\/21678421.2016.1259334","volume":"18","author":"RL Sufit","year":"2017","unstructured":"Sufit RL, Ajroud-Driss S, Casey P, Kessler JA. Open label study to assess the safety of VM202 in subjects with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(3\u20134):269\u201378.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"3","key":"4252_CR20","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/gt.2015.110","volume":"23","author":"MR Kibbe","year":"2016","unstructured":"Kibbe MR, Hirsch AT, Mendelsohn FO, Davies MG, Pham H, Saucedo J, et al. Safety and efficacy of plasmid DNA expressing two isoforms of hepatocyte growth factor in patients with critical limb ischemia. Gene Ther. 2016;23(3):306\u201312.","journal-title":"Gene Ther"},{"issue":"7","key":"4252_CR21","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/gt.2012.87","volume":"20","author":"JS Kim","year":"2013","unstructured":"Kim JS, Hwang HY, Cho KR, Park EA, Lee W, Paeng JC, et al. Intramyocardial transfer of hepatocyte growth factor as an adjunct to CABG: phase I clinical study. Gene Ther. 2013;20(7):717\u201322.","journal-title":"Gene Ther"},{"issue":"Pt 5","key":"4252_CR22","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1093\/brain\/120.5.813","volume":"120","author":"N Birouk","year":"1997","unstructured":"Birouk N, Gouider R, Le Guern E, Gugenheim M, Tardieu S, Maisonobe T, et al. Charcot-Marie-Tooth disease type 1A with 17p11.2 duplication. Clinical and electrophysiological phenotype study and factors influencing disease severity in 119 cases. Brain. 1997;120(Pt 5):813\u201323.","journal-title":"Brain"},{"issue":"12","key":"4252_CR23","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/S1474-4422(09)70260-1","volume":"8","author":"J Micallef","year":"2009","unstructured":"Micallef J, Attarian S, Dubourg O, Gonnaud PM, Hogrel JY, Stojkovic T, et al. Effect of ascorbic acid in patients with Charcot-Marie-Tooth disease type 1A: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2009;8(12):1103\u201310.","journal-title":"Lancet Neurol"},{"issue":"3","key":"4252_CR24","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/jns.12084","volume":"19","author":"R Sadjadi","year":"2014","unstructured":"Sadjadi R, Reilly MM, Shy ME, Pareyson D, Laura M, Murphy S, et al. Psychometrics evaluation of Charcot-Marie-Tooth Neuropathy Score (CMTNSv2) second version, using Rasch analysis. J Peripher Nerv Syst. 2014;19(3):192\u201396.","journal-title":"J Peripher Nerv Syst"},{"issue":"8","key":"4252_CR25","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1136\/jnnp.2005.081547","volume":"77","author":"RC Graham","year":"2006","unstructured":"Graham RC, Hughes RA. A modified peripheral neuropathy scale: the overall neuropathy limitations scale. J Neurol Neurosurg Psychiatry. 2006;77(8):973\u201376.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"4252_CR26","first-page":"270","volume":"68","author":"R Appasamy","year":"1993","unstructured":"Appasamy R, Tanabe M, Murase N, Zarnegar R, Venkataramanan R, Van Thiel DH, et al. Hepatocyte growth factor, blood clearance, organ uptake, and biliary excretion in normal and partially hepatectomized rats. Lab Invest. 1993;68(3):270\u201376.","journal-title":"Lab Invest"},{"issue":"3","key":"4252_CR27","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.hepres.2004.09.002","volume":"30","author":"A Ido","year":"2004","unstructured":"Ido A, Moriuchi A, Kim I, Numata M, Nagata-Tsubouchi Y, Hasuike S, et al. Pharmacokinetic study of recombinant human hepatocyte growth factor administered in a bolus intravenously or via portal vein. Hepatol Res. 2004;30(3):175\u201381.","journal-title":"Hepatol Res"},{"issue":"Pt 7","key":"4252_CR28","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1093\/brain\/123.7.1516","volume":"123","author":"KM Krajewski","year":"2000","unstructured":"Krajewski KM, Lewis RA, Fuerst DR, Turansky C, Hinderer SR, Garbern J, et al. Neurological dysfunction and axonal degeneration in Charcot-Marie-Tooth disease type 1A. Brain. 2000;123(Pt 7):1516\u201327.","journal-title":"Brain"},{"issue":"4","key":"4252_CR29","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1002\/mus.880120408","volume":"12","author":"J Berciano","year":"1989","unstructured":"Berciano J, Combarros O, Calleja J, Polo JM, Leno C. The application of nerve conduction and clinical studies to genetic counseling in hereditary motor and sensory neuropathy type I. Muscle Nerve. 1989;12(4):302\u201306.","journal-title":"Muscle Nerve"},{"issue":"1","key":"4252_CR30","doi-asserted-by":"publisher","first-page":"8316","DOI":"10.1038\/s41598-018-26704-x","volume":"8","author":"KR Ko","year":"2018","unstructured":"Ko KR, Lee J, Lee D, Nho B, Kim S. Hepatocyte growth factor (HGF) promotes peripheral nerve regeneration by activating repair Schwann cells. Sci Rep. 2018;8(1):8316.","journal-title":"Sci Rep"},{"issue":"4","key":"4252_CR31","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.1016\/j.bbrc.2018.08.054","volume":"503","author":"KR Ko","year":"2018","unstructured":"Ko KR, Lee J, Nho B, Kim S. C-fos is necessary for HGF-mediated gene regulation and cell migration in Schwann cells. Biochem Biophys Res Commun. 2018;503(4):2855\u201360.","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-026-04252-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04252-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04252-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:23:42Z","timestamp":1781637822000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-026-04252-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,5]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4252"],"URL":"https:\/\/doi.org\/10.1186\/s13023-026-04252-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4220356\/v1","asserted-by":"object"}]},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,5]]},"assertion":[{"value":"10 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the institutional review board at our institution (IRB No.SMC 2020\u201305-038\u2013003). This study was conducted in accordance with Good Clinical Practice as defined by the International Council on Harmonisation, the principles defined in the Declaration of Helsinki and its amendments, and all applicable national and international laws. All patients provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors hove no competing interests to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"148"}}